EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway
← catalyst calendarSponsored by Rhythm Pharmaceuticals, Inc. (industry) · RYTM — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
296actual
Sites
56
Countries
Canada, France, Germany +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-12-10 | actual | When the study began enrolling |
| Primary completion | 2025-12-22 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-30 | actual | The whole study's end, after follow-up |
| First posted | 2021-10-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Obesity
- Genetic Obesity
Interventions
- Drug: Setmelanotide
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFDifference in mean change in body weight in patients treated with setmelanotide compared to placebo, assessed as percent change in BMI
measured Baseline to 52 weeks
Publications
- PMID 39561769 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · RYTM's whole pipeline · Catalyst calendar · Every registered study · What changed